Publication — IRIC

Overexpression of CD200 is a Stem Cell-Specific Mechanism of Immune Evasion in AML.

Acute myeloid leukemia (AML) stem cells (LSCs) are capable of surviving current standard chemotherapy and are the likely source of deadly, relapsed disease. While stem cell transplant serves as proof-of-principle that AML LSCs can be eliminated by the immune system, the translation of existing immunotherapies to AML has been met with limited success. Consequently, understanding and exploiting the unique immune-evasive mechanisms of AML LSCs is critical.

Publication date
July 1, 2021
Principal Investigators
Herbrich S, Baran N, Cai T, Weng C, Aitken MJL, Post SM, Henderson J, Shi C, Richard-Carpentier G, Sauvageau G, Baggerly K, Al-Atrash G, Davis RE, Daver N, Zha D, Konopleva M
PubMed reference
J Immunother Cancer 2021;9(7)
PubMed ID
34326171
Affiliation
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.